Humanin
Preclinical ResearchHumanin
A mitochondria-derived peptide researched for neuroprotection, metabolic health, and longevity. Levels decline with age and are studied as a longevity biomarker.
Dose
0.1-1.0 mg
Route
SubQ injection, Nasal spray
Cycle
4-12 weeks
Storage
Refrigerated (2°C-8°C / 36°F-46°F), protected from light
What is Humanin?
Humanin (HN) is a 24-amino acid endogenous peptide derived from the mitochondrial genome (encoded by the mtDNA 16S rRNA gene). It was initially identified as a neuroprotective factor against Alzheimer's disease-related toxicity. Research has since expanded to explore its roles in metabolic regulation, cardiovascular health, and general anti-aging processes. Humanin exerts its effects by binding to various receptors, including formyl peptide receptor-like 1 (FPRL1) and the gp130 receptor, and through modulation of intracellular signaling pathways involved in cell survival, inflammation, and insulin sensitivity. Levels of Humanin have been observed to decline with age and in certain disease states, leading to its investigation as a potential therapeutic agent and biomarker.
Key Benefits
- Neuroprotection
- Alzheimer's research potential
- Insulin sensitivity improvement
- Cardiovascular protection
- Anti-aging potential
Mechanism of Action
- Binds FPRL1 and gp130 receptors
- Inhibits neuronal apoptosis
- Anti-inflammatory signaling
- Improves insulin sensitivity
Best For
- Longevity research
- Neuroprotection research
- Metabolic research
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
2408.7 g/mol
Length
24 amino acids
Type
Mitochondria-derived peptide
Amino acid sequence
MTLSEGEVGSGKLDAGVKLTACCYRP
N-terminal methionine, often modified or cleaved in biological systems; the 24-amino acid form is commonly studied.
Research Indications
Alzheimer's Disease Research
Extensively studied for its ability to inhibit neuronal apoptosis and protect against amyloid-beta toxicity in preclinical models, suggesting potential as a therapeutic agent for Alzheimer's.
Stroke and Ischemia-Reperfusion Injury
Research indicates Humanin's role in reducing neuronal damage and improving neurological outcomes following ischemic events in various animal models.
Neuroinflammation
Demonstrates anti-inflammatory properties within the central nervous system, which may contribute to its neuroprotective effects against various insults.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Neuroprotection (e.g., Alzheimer's models) | 0.5-1.0 mg | 3 times per week | Subcutaneous (or intranasal in some studies) |
| Metabolic Health (e.g., insulin sensitivity studies) | 0.3-0.7 mg | 2 times per week | Subcutaneous |
| General Longevity/Anti-aging Biomarker Modulation | 0.1-0.5 mg | 2-3 times per week | Subcutaneous |
| Acute Neuroprotection (e.g., post-stroke models in animals) | 1.0-2.0 mg (higher acute doses sometimes studied) | Daily for a short period (e.g., 3-7 days) | Subcutaneous or Intranasal |
| Intranasal Administration for CNS Targeting | 0.5-1.0 mg (as a nasal spray, specific formulation dependent) | Daily or 3 times per week | Intranasal |
Research protocols typically emphasize consistent administration for an extended period to observe potential effects.
Peptide Interactions
- Monitor Combination
Insulin/Insulin Sensitizers
Given Humanin's potential to improve insulin sensitivity, co-administration with insulin or other insulin sensitizers may require careful monitoring of blood glucose levels to prevent hypoglycemia in research settings.
- Synergistic
Antioxidants (e.g., NAC, ALA)
Some research suggests Humanin's protective effects may be enhanced when combined with other compounds that mitigate oxidative stress, though specific human data are limited.
- Compatible
Neurotrophic Factors (e.g., BDNF mimetics)
Theoretically compatible with other neurotrophic or neuroprotective agents, potentially contributing to a broader neuroprotective strategy in research.
- Monitor Combination
Inflammatory Modulators
Humanin has anti-inflammatory properties; co-administration with other anti-inflammatory agents could have additive effects, requiring monitoring.
- Compatible
Other Mitochondria-derived Peptides (e.g., MOTS-c, SHLP2)
While their mechanisms are distinct, combining mitochondria-derived peptides is an area of ongoing research interest, often exploring complementary benefits.
How to Reconstitute
- 1Gather supplies: lyophilized Humanin vial, bacteriostatic water for injection, sterile syringes, and alcohol wipes.
- 2Carefully remove the cap from the Humanin vial and wipe the stopper with an alcohol wipe.
- 3Draw the desired amount of bacteriostatic water (e.g., 1-2 mL for a 5mg vial) into a sterile syringe. Aim for a concentration that allows for accurate dosing.
- 4Slowly inject the bacteriostatic water into the Humanin vial, directing the stream against the side of the glass to avoid direct impact on the lyophilized powder.
- 5Do NOT shake the vial. Gently swirl the vial between your fingers until the powder is completely dissolved. This may take a few minutes.
- 6Visually inspect the reconstituted solution to ensure it is clear and free of particulate matter. If not, discard.
Reconstitution should be performed carefully to preserve peptide integrity. Bacteriostatic water for injection is commonly discussed for multi-dose vials to inhibit bacterial growth.
What to Expect
- Weeks 1-2: Initial research suggests potential for subtle changes in energy levels or overall well-being, though these are often difficult to discern at early stages.
- Weeks 3-6: Some studies indicate potential improvements in cellular markers related to metabolic health or inflammatory responses might begin to be observed in research subjects.
- Weeks 6-12: More pronounced effects related to neuroprotection or improved insulin sensitivity, as explored in animal and in vitro models, may become apparent in longer-term research protocols.
- Months 3-6: Longer research durations are often used to evaluate potential impacts on longevity parameters or chronic disease markers.
- Ongoing: Continued administration, as per specific research protocols, is generally required to maintain any observed effects, aligning with its proposed role in combating age-related decline.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Minimal reported | Rare | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.